Novo Nordisk CEO touts new drugs as investors remain wary
WSJ reports Novo Nordisk CEO Mike Doustdar said the company will launch several new blockbusters over the next few years, but investors are not yet convinced growth path is imminent.
WSJ reports Novo Nordisk CEO Mike Doustdar said the company will launch several new blockbusters over the next few years, but investors are not yet convinced growth path is imminent.